Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.40 |
| ▸ | DCUN1D2 | Q6PH85 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15288191 | 0.89 | PLK4 (0.36) | METAP2AKT1AKT2LMNAPDGFRA | |
| SCHEMBL29178051 | 0.85 | PTGES (0.42) | METAP2AKT1AKT2LMNAFGFR1 | |
| SCHEMBL10018 | 0.83 | SCN4A (0.46) | AKT1AKT2LMNASCN4AALDH1A1 | |
| SCHEMBL17283676 | 0.79 | SCN4A (0.43) | AKT1AKT2FGFR1CDK5CLK4 | |
| SCHEMBL4095775 | 0.79 | PTGS2 (0.43) | PIM1SCN4AALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL30568910 | 0.78 | METAP2 (0.38) | METAP2AKT1AKT2LMNARPS6KA3 | |
| SCHEMBL3175390 | 0.77 | SCN4A (0.45) | METAP2AKT1AKT2LMNASCN4A | |
| SCHEMBL5020238 | 0.76 | PBRM1 (0.43) | LMNADCUN1D1ALDH1A1HSD17B10HPGD | |
| SCHEMBL5020276 | 0.76 | IDO1 (0.43) | DCUN1D1NISCHALDH1A1HPGDIDO1 | |
| SCHEMBL5020179 | 0.76 | RAB9A (0.44) | METAP2LMNADCUN1D1NISCHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | METAP2 60/4885AKT1 4709/4885AKT2 4722/4885 |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | METAP2 60/4885AKT1 4709/4885AKT2 4722/4885 |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | METAP2 60/4885AKT1 4709/4885AKT2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.